|
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application
Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer.
Key Benefits
Novel molecule.
Novel target presents new path to lung cancer treatment.
Potentially extend survival rate of lung cancer patients.
Market Summary
Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020
Inventor(s): Xingming Deng
|
|
Chemotherapy Dose Calculator
Application
Software to calculate doses for more effective and safe clinical trial design.
Key Benefits
Intuitive, user-friendly software design.
Flexible parameter inputs and easily interpreted results.
Provides simulations to estimate recommended maximum tolerated dose (MTD).
Market Summary
Before entry to commercial market, novel therapeutics...
Published: 2/20/2020
Inventor(s): Zhengjia (nelson) Chen, Youyun Zheng, Michael (Mike) Kutner
|
|
Combination Therapy to Treat Pediatric Brain Tumor
Application
Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma.
Key Benefits
Drug combination targets cancer stem cells.
Increased apoptosis of cancer cells compared to current chemotherapeutic agents.
Market Summary
Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 1/28/2020
Inventor(s): Tobey MacDonald, Anna Kenney, James Felker, Abhinav Dey
|
|
Strategy to Identify miRNAs for Disease Diagnosis
Application
Method to measure precursor and mature miRNA specifically.
Key Benefits
Unique primers can specifically identify miRNAs and precursor miRNAs by standard qRT-PCR without the requirement for an additional detection probe.
Allows for amplification and quantification of both mature miRNA and precursor miRNAs.
Potential technology to evaluate...
Published: 1/22/2020
Inventor(s): Wenming Li
|
|
Small Molecule for Treatment-Resistant Lung Cancer
Application
Small molecule agonist for treating cancers involving KRAS mutations.
Key Benefits
Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC).
Selective for mutant KRAS lung cancer cells over normal cells.
Non-toxic to normal cells.
Market Summary
Lung cancer is the leading cause of cancer death in the US. Lung cancer...
Published: 1/14/2020
Inventor(s): Xingming Deng
|
|
High-Resolution Field Inhomogeneity Correction for Magnetic Resonance Spectroscopy
Application
Post-processing algorithm to correct field inhomogeneity in MR spectroscopy.
Key Benefits
Subvoxel field inhomogeneity correction enables CEST magnetic resonance imaging (MRI) Z-spectrum from body tissues where shimming is challenging.
Intravoxel field inhomogeneity correction enables MR spectroscopy (MRS) and MR spectroscopy imaging...
Published: 1/13/2020
Inventor(s): Phillip Zhe Sun
|
|
Combination Therapy Using Small Molecule Conjugation to Reovirus for TNBC Treatment
ApplicationSmall molecule inhibitor doxorubicin hydrochloride (Dox) conjugated to reovirus for targeted combination therapy of triple-negative breast cancer (TNBC).Key BenefitsTargeted treatment that directly infects and kills breast cancer cells.Increased cytopathicity, cytotoxicity and faster induction of cell death than virus alone.Enhanced selective...
Published: 10/11/2019
Inventor(s): Bernardo Mainou, Roxana Rodriguez, Angela Berger
|
|
Hybrid Proton-Photon Inverse Optimization to Deliver Radiation Therapy
Application
Hybrid proton-photon inverse optimization method that synergizes proton and photon therapy with improved total optimization objectives for robust cancer treatment delivery.
Key Benefits
Improved planning target volume coverage and organ at risk sparing.
Reduced overall optimization values.
Less expensive treatment than proton therapy...
Published: 10/11/2019
Inventor(s): Hao Gao
|
|
Targeted Anti-Cancer Nanoparticle Therapy
Application
A drug-carrying nanoparticle that selectively targets cancer cells.
Key Benefits
Incorporates an already proven anti-cancer therapeutic.
Increases deliverability.
Targets cancer cells.
Market Summary
Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 9/9/2019
Inventor(s): Jack Arbiser, Lily Yang
|
|
Beta Blocker Isomers as Angiogenesis Inhibitors
Application
β-blocker inactive form of propranolol for treatment of angiogenic disease.
Key Benefits
Reduced side-effects, such as low blood pressure and low blood sugar.
Increased anti-angiogenic activity compared to the active isoform.
Market Summary
Angiogenesis is the growth of blood vessels from the existing vasculature. While it...
Published: 7/29/2019
Inventor(s): Jack Arbiser
|
Emory UniversityOffice of Technology Transfer